Massachusetts Society of Clinical Oncologists - FDA approved atezolizumab (Tecentriq) for alveolar soft part sarcoma

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
For Professionals
FDA Approvals
FDA approved atezolizumab (Tecentriq) for alveolar soft part sarcoma

FDA approved atezolizumab (Tecentriq) for alveolar soft part sarcoma

12 Dec 2022 8:24 AM | Katy Monaco (Administrator)

Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS). Read more.

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329 | email: msco@mms.org